EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis

Guangzhong Guo, Ziyue Zhang, Jiubing Zhang, Dayang Wang, Sensen Xu, Guanzheng Liu, Yushuai Gao, Jie Mei, Zhaoyue Yan, Ruijiao Zhao, Meiyun Wang, Tianxiao Li und 1 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03774-7 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Guangzhong Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Juha International Center for Neurosurgery, Glioma Clinical Diagnosis and Treatment Center of Henan Province, Glioma Engi…. Hauptthemen laut MEDLINE: Glioblastoma, Bevacizumab, Circulating Tumor DNA, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Natural Science Foundation of Henan Province, the Research Foundation of the Health Commission of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Most recurrent glioblastoma (rGBM) patients do not benefit from immune checkpoint inhibition, emphasizing the necessity for response biomarkers. This study evaluates whether tumor in situ fluid (TISF) circulating tumor DNA (ctDNA) could serve as a biomarker for response to low-dose bevacizumab (Bev) plus anti-PD-1 therapy in rGBM patients, aiming to enhance systemic responses to immunotherapy.

Methods

In this phase II trial, 32 GBM patients with first recurrence after standard therapy were enrolled and then received tislelizumab plus low-dose Bev each cycle. TISF samples were analyzed for ctDNA using a 551-gene panel before each treatment.

Results

The median progression-free survival (mPFS) and overall survival (mOS) were 8.2 months (95% CI, 5.2–11.1) and 14.3 months (95% CI, 6.5–22.1), respectively. The 12-month OS was 43.8%, and the objective response rate was 56.3%. Patients with more than 20% reduction in the mutant allele fraction and tumor mutational burden after treatment were significantly associated with better prognosis compared to baseline TISF-ctDNA. Among detectable gene mutations, patients with MUC16 mutation, EGFR mutation & amplification, SRSF2 amplification, and H3F3B amplification were significantly associated with worse prognosis.

Conclusions

Low-dose Bev plus anti-PD-1 therapy significantly improves OS in rGBM patients, offering guiding significance for future individualized treatment strategies. TISF-ctDNA can monitor rGBM patients' response to combination therapy and guide treatment. Clinical trial registration This trial is registered with ClinicalTrials.gov, NCT05540275.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBevacizumabCirculating Tumor DNAImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalBrain NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorPrognosis

Stichwörter der Autor:innen

BiomarkersCirculating tumor DNAGlioblastomaPhase II trialsPrognosisRecurrence

Substanzen

BevacizumabCirculating Tumor DNAImmune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Juha International Center for Neurosurgery, Glioma Clinical Diagnosis and Treatment Center of Henan Province, Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan…
  • Department of Cerebrovascular Disease, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.
  • Department of Pathology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.
  • Department of Radiology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, China.
  • Henan Provincial Neurointerventional Engineering Research Center, Henan International Joint Laboratory of Cerebrovascular Disease, Henan Engineering Research Center of Cerebrovascular Intervention Innovation, Zhengzhou,…

ORCID-Profile: Xingyao Bu

Förderung

  • the Natural Science Foundation of Henan Province
  • the Research Foundation of the Health Commission of Henan Province

Zitieren

APA

Guo, G., Zhang, Z., Zhang, J., Wang, D., Xu, S., Liu, G., Gao, Y., Mei, J., Yan, Z., Zhao, R., Wang, M., Li, T., & Bu, X. (2024). Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03774-7

Vancouver

Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, et al. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03774-7

BibTeX
@article{Guo2024,
  author = {Guo, Guangzhong and Zhang, Ziyue and Zhang, Jiubing and Wang, Dayang and Xu, Sensen and Liu, Guanzheng and Gao, Yushuai and Mei, Jie and Yan, Zhaoyue and Zhao, Ruijiao and Wang, Meiyun and Li, Tianxiao and Bu, Xingyao},
  title = {Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03774-7}
}
Kostenlos starten →